Clinical trial · Observational
Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion
NCT05532475CI-TRIAL-00083039completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate the association of vitreous tumor necrosis factor with the pathogenesis of retinal vein occlusion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Retinal Vein Occlusion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| measurement of vitreous level of tumor necrosis factor alpha | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- cases
- description
- patient with retinal vein occlusion
- interventionNames
- Diagnostic Test: measurement of vitreous level of tumor necrosis factor alpha
- label
- control
- description
- cataract patient undergoing cataract surgery
- interventionNames
- Diagnostic Test: measurement of vitreous level of tumor necrosis factor alpha
Primary outcomes (1)
- measure
- to assess vitreous level of tumor necrosis factor alpha in retinal vein occlusion and compare it to patient undergoing cataract surgery
- timeFrame
- Day 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Any patient with retinal vein occlusion not older than 6 months with no history of Anti-VEGF injection Exclusion Criteria: 1. Diabetic patients. 2. Other causes of retinal vascular diseases. 3. Patients with history of treatment of retinal vein occlusion. 4. Previous intraocular surgery except cataract surgery performed 6 months before the study. 5. Subjects with severe systemic inflammatory diseases 6. Retinal vein occlusion secondary to retinal vasculitis. 7. All retinal pathologies. 8. Patients receiving Systemic steroids or Immunosuppressive therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.